Last reviewed · How we verify
Diethyl Methyl Carbinol Urethan (EMYLCAMATE)
Diethyl Methyl Carbinol Urethan (generic name: EMYLCAMATE) is a emylcamate drug. It is currently in Phase 2 development.
EMYLCAMATE is thought to work by interacting with a specific target in the body, although the exact mechanism is not well understood.
Diethyl Methyl Carbinol Urethan (EMYLCAMATE) is a small molecule drug in the emylcamate class, but its target and approved indications are unknown. Its commercial status, including patent status and generic manufacturers, is also unclear. As a result, key safety considerations and pharmacokinetic properties such as half-life and bioavailability are not well established. Further research is needed to understand the potential benefits and risks of this compound. Its current owner is also unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | EMYLCAMATE |
|---|---|
| Drug class | emylcamate |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and the target is the key that fits into those locks. When EMYLCAMATE binds to the target, it can affect how the cells work, potentially leading to changes in the body's chemistry. However, the exact way it works is still a mystery.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diethyl Methyl Carbinol Urethan CI brief — competitive landscape report
- Diethyl Methyl Carbinol Urethan updates RSS · CI watch RSS
Frequently asked questions about Diethyl Methyl Carbinol Urethan
What is Diethyl Methyl Carbinol Urethan?
How does Diethyl Methyl Carbinol Urethan work?
What is the generic name of Diethyl Methyl Carbinol Urethan?
What drug class is Diethyl Methyl Carbinol Urethan in?
What development phase is Diethyl Methyl Carbinol Urethan in?
Related
- Drug class: All emylcamate drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing